The primary goal of the Cancer Genetics and Metabolism (CGM) Program is to support the clinical, translational, and basic research missions of the Wake Forest Baptist Comprehensive Cancer Center (WFBCCC) related to two fundamental hallmarks of cancer: genetic alterations and metabolic reprogramming. There are numerous unmet needs in these areas for extensive research in mechanism, clinical association, and therapeutic opportunities. Members of the CGM Program synergize their efforts to carry out well-rounded research projects organized in two specific aims: 1) to understand the deregulated cancer genome and its implications in prognostics and therapeutics; and 2) to interrogate cancer metabolic alterations and develop novel therapeutic approaches. The ultimate goal is the greater understanding of the interactions between both hallmarks to improve the lives of patients with cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA012197-46
Application #
10093005
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-02-01
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
46
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Type
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Melvin, Ryan L; Xiao, Jiajie; Berenhaut, Kenneth S et al. (2018) Using correlated motions to determine sufficient sampling times for molecular dynamics. Phys Rev E 98:023307
Bhatt, Nikunj B; Pandya, Darpan N; Dezarn, William A et al. (2018) Practical Guidelines for Cerenkov Luminescence Imaging with Clinically Relevant Isotopes. Methods Mol Biol 1790:197-208
Gesell, Sabina B; Golden, Shannon L; Limkakeng Jr, Alexander T et al. (2018) Implementation of the HEART Pathway: Using the Consolidated Framework for Implementation Research. Crit Pathw Cardiol 17:191-200
Mao, Chengqiong; Qu, Ping; Miley, Michael J et al. (2018) P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates. Biomater Sci 6:3063-3074
Bhatt, Nikunj B; Pandya, Darpan N; Rideout-Danner, Stephanie et al. (2018) A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents. Dalton Trans 47:13214-13221
Andrews, Rachel N; Caudell, David L; Metheny-Barlow, Linda J et al. (2018) Fibronectin Produced by Cerebral Endothelial and Vascular Smooth Muscle Cells Contributes to Perivascular Extracellular Matrix in Late-Delayed Radiation-Induced Brain Injury. Radiat Res 190:361-373
Zhao, Yan; Li, Fang; Mao, Chengqiong et al. (2018) Multiarm Nanoconjugates for Cancer Cell-Targeted Delivery of Photosensitizers. Mol Pharm 15:2559-2569
Samykutty, Abhilash; Grizzle, William E; Fouts, Benjamin L et al. (2018) Optoacoustic imaging identifies ovarian cancer using a microenvironment targeted theranostic wormhole mesoporous silica nanoparticle. Biomaterials 182:114-126
Xiao, Jiajie; Melvin, Ryan L; Salsbury Jr, Freddie R (2018) Probing light chain mutation effects on thrombin via molecular dynamics simulations and machine learning. J Biomol Struct Dyn :1-18
Mao, Chengqiong; Zhao, Yan; Li, Fang et al. (2018) P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors. J Control Release 286:289-300

Showing the most recent 10 out of 548 publications